(Co. Reg. No: 200405621W)

NEWS RELEASE

iX Biopharma announces appointment of Chief Commercial Officer

Singapore, 18 January 2021 – Specialty pharmaceutical company **iX Biopharma Ltd** (SGX:42C) ("iX Biopharma", "the Company" or together with its subsidiaries, "the Group") is pleased to announce the appointment of Ms. Eva Tan as its new Chief Commercial Officer (CCO) effective immediately. Prior to the appointment, Ms. Tan was formerly iX Biopharma's Director of Corporate and Commercial Strategy, overseeing the commercial, legal and corporate matters pertaining to the Group.

Since joining iX Biopharma in September 2017, Ms. Tan has led the Group in the commercialisation of its pharmaceutical, nutraceutical and medicinal cannabis business segments. Ms Tan spearheaded the market launch of the Entity line of nutraceuticals in 2019, which is now sold through more than 250 pharmacies and health food stores in Australia. She is driving the Group's commercial push into China, which saw the Group secure in quick succession the establishment of 2 Entity flagship stores on Tmall and JD and the licensing of its sublingual sildenafil wafers to a Chinese pharmaceutical company for the China market. As the newly appointed CCO, Ms Tan will be responsible for the development and execution of the Group's global commercial strategies across all segments.

Mr Eddy Lee, Chairman & CEO of iX Biopharma, comments: "*The Company is undergoing an exciting transition of its focus from R&D to commercialisation. We have appointed Eva into this important new position to support the Group's transformation. Eva's execution capabilities, track record and deep understanding of the Group's businesses make her a strong addition to our executive management team and primes the Group to enter a new phase of growth.*"

Prior to joining the Company, Ms. Tan was a corporate lawyer at a leading law firm in Singapore, where she specialised in the capital markets practice. Ms. Tan was involved in numerous local and international IPOs, including the listing of iX Biopharma on the SGX Catalist in 2015.

- The End -

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("**Sponsor**") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place #09-01 Singapore Land Tower Singapore 048623, telephone: +65 6337 5115.